key: cord-0882369-hrhuqs88
authors: Lau, Colleen L; Mayfield, Helen J; Sinclair, Jane E; Brown, Samuel J; Waller, Michael; Enjeti, Anoop K; Baird, Andrew; Short, Kirsty; Mengersen, Kerrie; Litt, John
title: Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework
date: 2021-11-04
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.10.079
sha: c2407872859c3cbd4477d0663b4661b2c6c97d50
doc_id: 882369
cord_uid: hrhuqs88

Thrombosis and Thromobocytopenia Syndrome (TTS) has been associated with the AstraZencea (AZ) COVID-19 vaccine (Vaxzevria). Australia has reported low TTS incidence of <3/100,000 after the first dose, with case fatality rate (CFR) of 5-6%. Risk-benefit analysis of vaccination has been challenging because of rapidly evolving data, changing levels of transmission, and age-specific variation in rates of TTS, COVID-19, and CFR. We aim to optimise risk-benefit analysis by developing a model that enables inputs to be updated rapidly as evidence evolves. A Bayesian network was used to integrate local and international data, government reports, published literature and expert opinion. The model estimates probabilities of outcomes under different scenarios of age, sex, low/medium/high transmission (0.05%/0.45%/5.76% of population infected over 6 months), SARS-CoV-2 variant, vaccine doses, and vaccine effectiveness. We used the model to compare estimated deaths from vaccine-associated TTS with i) COVID-19 deaths prevented under different scenarios, and ii) deaths from COVID-19 related atypical severe blood clots (cerebral venous sinus thrombosis & portal vein thrombosis). For a million people aged ≥70 years where 70% received first dose and 35% received two doses, our model estimated <1 death from TTS, 25 deaths prevented under low transmission, and >3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to >4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58-126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk-benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines.

The AstraZeneca ChAdOx1 (AZD1222) COVID-19 vaccine, Vaxzevria (AZ vaccine) has been widely used globally, with one billion doses released in over 170 countries by August 2021 [1] . The vaccine has been reported to be 40-90% effective against symptomatic infection, and 75-90% effective against death from COVID-19 [2] [3] [4] [5] . In March 2021, reports of AZ vaccine-associated Thrombosis with Thrombocytopenia Syndrome (TTS) began emerging from multiple countries, including Norway [6] , Canada [7] , the U.K. [8] , and Australia [9] , and appeared to be more common in younger age groups [9] . Although the incidence of TTS was very low (<3/100,000 first doses in Australia), initial reports of high case fatality rates (CFR) (44% in Germany [10] and 18% in United Kingdom [8]) prompted some countries to recommend alternative COVID-19 vaccines in younger persons.

In Australia, a change in recommendation was made in April 2021 to preference the Pfizer/BioNTech On 29 June 2021, the Australian Government produced a document on 'Weighing up the potential benefits against the risk of harm from COVID-19 Vaccine AstraZeneca' for clinicians to help patients make informed decisions [16] . The document provides helpful information for each age group such as the risk of TTS versus the number of deaths, intensive care unit (ICU) admissions, and hospitalisations prevented by vaccination under low, medium, and high levels of transmission. However, calculations of risks versus benefits changed rapidly because of many factors, including evolving incidence and CFR The model could also be extended for outcomes other than death (e.g., ICU admission, long COVID), other vaccines, other adverse events following immunization (AEFI), or adapted for use in other countries.

BNs are acyclic graphical models that explicitly represent relationships between variables in terms of conditional probabilities [17] . Variables are represented by nodes, each categorized into several possible states (e.g., yes/no, high/low, age groups). Links (or edges) represent the relationships between nodes and point in the direction from a parent node (independent variable) to a child node (dependent variable) ( Figure 1 ). Nodes are quantified using probability tables that define the probability of a node being in a given state, either based on some prior distribution (for nodes with no parent nodes) or conditional on the states of all parent nodes i.e., conditional probability tables (CPTs Technical Advisory Group on Immunisation (ATAGI) and the Therapeutic Goods Administration (TGA), e.g., using the same age groups and definitions of low/medium/high community transmission intensity (equivalent to 0.05%/0.45%/5.76% of population infected over 6 months) [16] .

TTS is a rare and atypical form of blood clotting associated paradoxical thrombosis and low platelets. 

While the assumptions and model structure are defined by experts, the CPTs were based on empirical data. Experts compiled evidence from peer-reviewed literature, government websites and reports, and through discussion with external clinical experts (e.g., haematologists regarding the evidence for AZ vaccine-associated TTS, and background rates of CVST and PVT). Official data from Australian authorities were used wherever possible (e.g., local data on AZ vaccine-associated TTS). Otherwise, data were obtained from other robust and publicly available sources (e.g., background rates of CVST and PVT). Data from different sources were harmonised for the CPTs, e.g., summarising data to match the age groups used in the BN. Data analyses were conducted for some variables to convert them into probabilities for the CPTs, e.g., converting incidence of COVID-19 into probability of infection over 6 months for the Intensity of local transmission node. 

The 

We assessed the risks versus benefits of the AZ vaccine if 70% of the population received the first dose, and 35% had two doses. For this paper, the priors were chosen to represent vaccination coverage at the time of model development, but other priors can be used. We compared the following risks (vaccineassociated TTS) and benefits (potential deaths prevented) assuming the above vaccination coverage:

i) Estimated deaths per million under low, medium, and high transmission scenarios (equivalent to 0.05%/0.45%/5.76% of population infected over 6 months), and potential deaths prevented by vaccination;

ii) Estimated deaths per million from AZ vaccine-associated TTS;

iii) Estimated deaths per million from CVST and PVT in COVID-19 patients (i.e., those with symptomatic infection), and potential deaths prevented by vaccination.

During the development of the model, data and evidence for many of the inputs continually evolved.

To determine how often model assumptions need to be updated, sensitivity analysis was conducted for three predictor variables that were considered most likely to change over time. We examined actual changes in the reported incidence of AZ vaccine-associated TTS cases and deaths in Australia in August-September 2021. We also examined i) plausible differences in age-specific CFR for COVID-19 in Australia (e.g., if higher CFR with new variants or because of an overwhelmed health system, and

ii) plausible reductions in vaccine effectiveness against symptomatic COVID-19 infection and death.

From July-September 2021, reported incidence of AZ vaccine-associated TTS and related deaths in Australia fluctuated by week because of low numbers.

We examined ATAGI reports from 25/8/2021, 1/9/2021, 8/9/2021, and 15/9/2021 [37] to determine how fluctuations in data affected our model predictions of age-specific TTS-related deaths.

By 31/8/2021, COVID-19 CFRs in Australia were very low for younger age groups, with less than five deaths during the entire pandemic in each male/female subgroups in those aged 0-9, 10-19, 20-29, 30-39, and 40-49 years. We examined changes in CFR if (theoretically) there was one extra death or five extra deaths in each age-sex subgroup, and the potential impact of these changes on model predictions on COVID-19 related deaths.

We examined the sensitivity of model outputs to reduced vaccine effectiveness against the delta variant using theoretical assumptions of 5% and 10% reduction in effectiveness against both symptomatic infection and death.

The final BN structure ( Figure 2 ) synthesises the assumptions regarding probabilistic relationships between variables and outcomes. Table 2 provides a summary of all nodes (n1 to n20) and their parent/child relationships. The model was designed to predict five outcomes:

i. Probability of dying from AZ vaccine-associated TTS (n6) -depending on age (n2), 1 st or 2 nd dose of AZ vaccine (n1);

ii. Background probability of deaths from CVST and PVT (in those who have not had AZ vaccine or COVID-19 infection) (n7, n8). Estimates were converted to probability of events over 6 weeks to enable comparison with the probability of vaccine-associated TTS (generally occurs within 6 weeks of vaccination);

iii. Probability of symptomatic COVID-19 infection -depending on age (n2), sex (n5), variant The BN includes five input nodes (orange) that could be used for scenario analysis based on AZ vaccine doses (n1), age (n2), sex (n5), variant (n3) and intensity of community transmission (n4). Community transmission scenarios were converted to probability of infection over six months to more readily compare the risks versus benefits of vaccination, which is expected to be effective for at least six months. Scenarios were selected based on ATAGI definitions of low/medium/high risk [16] , other scenarios that users could relate to (e.g., 1000 cases/day in NSW), and general scenarios that could be 

A model walk-through indicated that subject matter experts agreed the model structure matched their understanding of the problem space in terms of the relevant predictors and relationships drawn from the external data sources. Independent manual calculations by three authors (CLL, MW, KM) of probabilities of selected outcomes were consistent with model predictions (Appendix B).

A minor anomaly was detected in the model through assessment of biological plausibility. For COVID-dying from COVID-19 was lower than the probability of dying from COVID-19 related atypical severe blood clots. The reason for this anomaly is that data for COVID-19 CFR in Australia were used for the CPTs, and there have been no deaths to date in these age-sex subgroups (Table A3) , while data on COVID-19 related atypical blood clots were extracted from a study where data were predominantly sourced from the USA and Europe, where high CFRs could have resulted from an overwhelmed health system during the outbreak. Although the discrepancies in probabilities were extremely low (probability of dying from COVID-19 related atypical blood clots <0.0002% higher than dying from COVID-19 itself), the anomaly highlights that the model predictions should be interpreted as broad estimates rather than exact risks.

Model version 2 was used to estimate COVID-19 deaths prevented over 6 months per million population if 70% had a first dose, and 35% had two doses. The model shows that for a million people aged 70 years where 70% have had first dose and 35% two doses, an estimated 25 deaths would be prevented under low transmission (Fig 3a) versus >3000 deaths prevented under high transmission (Fig 3c) , with <1 expected death from TTS (Fig 3d) . 

Up to 25/8/2021 in Australia, age-specific incidence of AZ vaccine-associated TTS cases ranged from 16 to 27 per million first doses (Table 1) , with an overall CFR of ~5% (6 deaths out of 115 cases).

Based on annual background rates of CVST and PVT reported by Kristoffersen et al.

[28], Ageno et al.

[29], and Søgaard et al.

[30] our model estimated 6-week incidence of 0.38 (age <20 years) to 2.69 (age 70 years) cases per million, and overall CFR ranging from 7.0% to 21.6% from youngest to oldest age groups (Table A7 ). The background CFR for CVST and PVT (combined) range from 0.03 (age <20 years) to 0.58 (age 70 years) per million over 6 weeks, compared to CFR of 0.83 to 1.40 per million first doses of AZ vaccine depending on age (Table 3) .

Model assumptions on the incidence and CFR of CVST and PVT in COVID-19 patients were obtained from a retrospective cohort study using linked electronic health records predominantly from the USA and Europe [32] because there were insufficient data from Australia. Model version 1 estimated that overall fatality from atypical severe blood clots (CVST and PVT combined) in COVID-19 patients were 51.1 and 37.3 per 100,000 in males and females, respectively. Figure 4 shows that the probability of developing atypical blood clots if infected (in those with symptomatic infection) was 14-28 times higher than developing TTS after the first dose of the AZ vaccine, depending on age group and sex (Figure 4 , dashed lines). The probability of dying from atypical blood clots if infected (in those with symptomatic infection) was 58-126 times higher than dying from TTS after the first dose of AZ vaccine, again depending on age group and sex (Figure 4 , solid lines). 

Our model shows that for a population where 70% has received the first dose and 35% has received two doses, a theoretical 5% or 10% reduction in vaccine effectiveness against the delta variant results in a 7.1% or 15.1% increase in estimated deaths, respectively (Table 4) . Therefore, sensitivity analyses

show that model predictions of deaths are much more sensitive to changes in vaccine effectiveness than to changes in incidence and CFR of TTS, or changes in CFR from COVID-19 infection. Data on vaccine effectiveness should be therefore be regularly reviewed and updated in the model.

Our model demonstrates that risk-benefit analysis of the AZ vaccine is complex, and depends on in COVID-19 patients are estimated to be 58-126 times more likely than after the first dose of the AZ vaccine ( Figure 4 ).

Sensitivity analyses showed that the estimates of COVID-19 related deaths were very sensitive to changes in vaccine effectiveness. Therefore, model assumptions need to be updated to reflect evolving evidence on vaccine effectiveness against current and future variants of the virus, waning immunity over time, and effectiveness of vaccine boosters. From a public health perspective, our findings suggest that a decrease in vaccine effectiveness will likely have important implications on disease burden. In contrast, model outputs were not very sensitive to changes in age-specific CFR for COVID-19, and updates to model assumptions are unlikely to be required unless changes are dramatic.

We used an innovative and flexible modelling framework which allows model assumptions to be easily changed, either to reflect new data (e.g., vaccine effectiveness), to the evolving situation (e.g., intensity of community transmission, changing CFR from TTS and COVID-19). While the current model is designed to estimate deaths from vaccine versus disease, it could be readily adapted for other outcomes (e.g., ICU admission, long COVID), other adverse events (e.g., immune thrombocytopenia), riskbenefit assessment of other vaccines (e.g., myocarditis/pericarditis from mRNA vaccines), and other types of scenario analysis (e.g., different combinations of vaccine doses and boosters). Our modelling approach also enables the use of multiple sources of data. We have used Australian data wherever possible and international sources if needed (e.g., low number of COVID-19 cases and vaccinations in Australia means that international data on vaccine effectiveness were likely to be more accurate). Our modelling approach therefore provides the potential for countries to develop a locally relevant risk- Our results should be interpreted considering the model's limitations. There are uncertainties associated with some of our model inputs, either because of limited data, or the use of data from other countries.

As illustrated with the anomaly regarding the risk of dying in younger persons, model outputs should be considered as broad estimates rather than exact risks, but estimates can be improved over time as more data become available. Our model provides population level estimates and does not consider individual risks such as behaviour and comorbidities. We plan to develop future models that include the individual's comorbidities, similar to the QCOVID tool [42] but specific for the Australian context.

In the results provided, we have assumed that 100% of infections were from the delta variant.

Assumptions of age distribution of delta cases (if unvaccinated) were obtained from data during the early stages of the delta outbreak in NSW from June 2021. While vaccination rates were relatively low then, older ages had higher vaccine coverage so infection rates for delta may have been underestimated in these groups. Data on CVST and PVT were obtained from studies outside Australia and may not reflect the local experience. While data used in the model were based on evidence rather than expert elicitation, we accept that biases, including information cascades, could still influence what evidence was gathered. We minimised these risks by encouraging experts to search the literature broadly and having regular group discussions (including with professional advisory groups) about where evidence could be challenged. The current model focuses on fatalities from COVID-19, TTS, and atypical blood clots, but does not consider other risks (e.g., adverse events) or other benefits (e.g., cases of severe COVID prevented, or broader societal benefits). It is important to note that the model uses a 6-month time frame for COVID-19 related outcomes and 6-weeks for background rates of CVST and PVT; these time horizons could be updated as evidence evolves. Our model was not parameterised from any specific datasets, so model outputs could not be directly validated by data. Nevertheless, the model provides a powerful mechanism for complex synthesis of multiple sources of data, and the outputs reflect the latest available knowledge.

In conclusion, we developed a novel approach to risk-benefit analysis for the AZ vaccine by using an adaptable BN modelling framework. Our model enables more precise risk analysis based on demographics, the outbreak situation, local data on vaccine-associated TTS, and the best available international evidence on vaccine effectiveness and atypical blood clots. purposes only. The model assumes 90% vaccine effectiveness against death and even distribution of males or females in the population; these numbers are entered as priors because the nodes do not have parents. The model assumes case fatality rate of 20% in males and 10% in females. The CPT for Die from Covid shows that if the vaccine is effective, probability of dying is 0% for both genders. If the vaccine is not effective, the probability of dying is 20% for males and 10% and females. Fig 1a) shows the BN in its default state; if the vaccine was 90% effective, we expect an overall 1.5% chance of dying from COVID (e.g., in a population of 1000 people, the vaccine was not effective in 100 people. Of these 100 people, we estimate 10 deaths out of 50 males, and 5 deaths out of 50 females, i.e., total of 15 deaths out of 1000 people, or 1.5%). Fig 1b) shows Estimated rate per 100,000 after 2 nd dose of AZ vaccinations: 0.18 per 100,000 (no age specific rates available).

Case fatality rate in Australia ~5% (noting that higher rates reported in UK ~18%).

For sensitivity analysis, data from ATAGI reports on 1/9/2021, 8/9/2021, and 15/9/2021 were used.

Background rates of atypical venous thrombotic disorders Background rates (in population not infected with and not vaccinated for COVID-19) of atypical venous thrombotic disorder (CVST and PVT) over 6 weeks were calculated for each age group to provide a comparison with chance of TTS after AZ vaccine. 

Oxford vaccine reaches one billion doses released

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet

Vaccine Effectiveness Expert Panel (VEEP) VEEP: Vaccine effectiveness table

Norwegian Institute of Public Health Norwegian Institute of Public Health's recommendation about AstraZeneca vaccine

Timm Bruch Alberta doctors find 2nd case of blood clot linked to

Australian Government Department of Health ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca

Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination -A riskbenefit analysis for people < 60 years in Australia. Vaccine

Vaccine willingness and concerns in Australia

Australian Government Department of Health COVID-19 summary statistics. Coronavirus (COVID-19) case numbers and statistics

Australian Government Department of Health COVID-19 vaccination -Weighing up the Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using an adaptable Bayesian network modelling framework ABSTRACT

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: a